Business Context and Reporting Period
This summary covers the Form 10-K for Schering-Plough Corporation for the fiscal year ended December 31, 2008. Schering-Plough is a global health care company operating in three segments: Prescription Pharmaceuticals, Animal Health, and Consumer Health Care. The 2008 reporting period was defined by the full-year integration of the Organon BioSciences N.V. (OBS) acquisition (closed November 2007), which significantly expanded the company's portfolio in Women's Health, Central Nervous System, and Animal Health. The company also faced significant headwinds regarding its cholesterol franchise (VYTORIN and ZETIA) due to clinical trial results and regulatory scrutiny.
Key Financial Metrics
| Metric | 2008 | 2007 | Change |
|---|---|---|---|
| Net Sales | $18,502 million | $12,690 million | +46% |
| Net Income | $1,903 million | $(1,473 million) | Turnaround to Profit |
| Net Income Available to Common Shareholders | $1,753 million | $(1,591 million) | Turnaround to Profit |
| Diluted EPS | $1.07 | $(1.04) | N/A |
| Operating Cash Flow | $3,364 million | $2,630 million | +28% |
| Long-Term Debt | $7,931 million | $9,019 million | -12% |
| Total Assets | $28,117 million | $29,156 million | -4% |
| Shareholders' Equity | $10,529 million | $10,385 million | +1% |
Note: 2007 results included a $3.8 billion non-cash charge for acquired in-process research and development (IPR&D) related to the OBS acquisition, which caused a reported net loss for that year.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 46% to $18.5 billion, driven primarily by the inclusion of OBS products ($5.4 billion in sales) and growth in key products like REMICADE (+28%), NASONEX (+6%), and TEMODAR (+16%).
- Profitability: The company returned to profitability with $1.9 billion in net income, reversing the 2007 loss. This was aided by the absence of the 2007 IPR&D charge and a $160 million gain on the divestiture of certain Animal Health products.
- Cholesterol Franchise Decline: Global combined sales of VYTORIN and ZETIA decreased 11% in 2008. U.S. sales for these products dropped 24% due to market share loss following the ENHANCE clinical trial results.
- Segment Performance:
- Prescription Pharmaceuticals: Sales rose 40% to $14.3 billion; profit was $2.7 billion (including $808 million in purchase accounting charges).
- Animal Health: Sales surged 138% to $3.0 billion due to the OBS acquisition; profit was $186 million (including a $160 million divestiture gain).
- Consumer Health Care: Sales were flat at $1.3 billion; profit was $271 million.
- Debt Reduction: Long-term debt decreased by approximately $1.1 billion as the company paid down euro-denominated debt and commercial paper.
Guidance, Outlook, and Risks
- 2009 Outlook: Management does not provide numeric guidance. They expect U.S. sales of VYTORIN and ZETIA to be lower in 2009, while international sales (excluding foreign exchange) should continue to grow. R&D spending is expected to grow in the mid-single-digit range.
- Productivity Transformation Program (PTP): Announced in April 2008, this program targets $1.5 billion in annualized savings by 2012 through cost reduction and OBS integration synergies. Approximately $1.25 billion is expected by the end of 2010.
- Key Risks and Contingencies:
- Cholesterol Litigation: Ongoing investigations by Congress, the DOJ, and state Attorneys General regarding the ENHANCE and SEAS clinical trials. Multiple class-action lawsuits are pending alleging consumer fraud and securities violations.
- Patent Challenges: Pending Paragraph IV certifications for key products including TEMODAR, ZETIA, and CLARINEX.
- Regulatory Environment: Increased scrutiny on drug safety, pricing pressures from government and managed care, and potential healthcare reform in the U.S.
- Tax Matters: Ongoing litigation with the IRS regarding interest rate swaps from 1991-1992; a decision is pending in the U.S. District Court for New Jersey.
Investor Verification Checklist
- Cholesterol Franchise Trajectory: Verify the impact of the ENHANCE and SEAS trial results on future VYTORIN/ZETIA sales and the status of the pending IMPROVE-IT trial.
- Legal Exposure: Assess the potential financial impact of the ongoing government investigations and class-action lawsuits related to the cholesterol joint venture.
- OBS Integration Progress: Confirm the realization of the targeted $1.5 billion in savings from the Productivity Transformation Program and the successful integration of OBS R&D pipelines.
- Patent Expirations: Review the timeline for patent expirations on key products like TEMODAR (EU 2009) and FOLLISTIM/PUREGON (EU 2009) and the status of generic challenges.
- Tax Litigation Outcome: Monitor the resolution of the IRS dispute regarding the 1991-1992 interest rate swaps, which involves a potential refund of over $470 million.